Abstracts tagged "Janus kinase (JAK) and rheumatoid arthritis"

Abstract Number: 46 • 2019 ACR/ARP Annual Meeting
Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Rachael Hawtin ², Jinfeng Liu ² and Amer M. Mirza ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Kevin Winthrop¹, Mark Genovese ², Bernard Combe ³, Yoshiya Tanaka ⁴, Alan Kivitz ⁵, Franziska Matzkies ⁶, Beatrix Bartok ⁶, Lei Ye ⁶, Ying Guo ⁶, Chantal Tasset ⁷, John Sundy ⁶, Edward Keystone ⁸, Rene Westhovens ⁹, William F.C. Rigby ¹⁰ and Gerd Burmester ¹¹, ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…
Abstract Number: 574 • 2018 ACR/ARHP Annual Meeting
Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily
Roy Fleischmann¹, Mark C. Genovese², Anabela Cardoso³, Luna Sun³, Yun-Fei Chen³, Chad D. Walls³, Douglas E. Schlichting³, Tsutomu Takeuchi⁴, Maxime Dougados⁵, Josef S. Smolen⁶ and Jeffrey R. Curtis⁷, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University Medical Center, Palo Alto, CA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵Paris Descartes University, Hôpital Cochin, Paris, France, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor, has shown clinical efficacy in patients (pts) with RA and an inadequate response to conventional…
Abstract Number: 2826 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate
Mark C. Genovese¹, Maria Greenwald², Christine Codding³, Mario H. Cardiel⁴, Anna Zubrzycka-Sienkiewicz⁵, Alan J. Kivitz⁶, Steve Wisseh⁷, Kathyjo Shay⁸ and Jay P. Garg⁸, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Desert Medical Advances, PALM DESERT, CA, ³Health Research of Oklahoma, Oklahoma City, OK, ⁴Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁵ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Biocis, Chicago, IL, ⁸Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: 948 • 2014 ACR/ARHP Annual Meeting
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Alan J. Kivitz¹, Anna Zubrzycka-Sienkiewicz², Sergio R. Gutierrez-Ureña³, Jeffrey Poiley⁴, Rita Kristy⁵, Kathyjo Shay⁵ and Jay P. Garg⁵, ¹Altoona Center for Clinical Research, Duncansville, PA, ²ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, ³Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, ⁴Arthritis Associates, Orlando, FL, ⁵Astellas Pharma Global Development, Northbrook, IL
Background/Purpose ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA). ASP015K inhibits JAK 1/3 with relative…
Abstract Number: L12 • 2012 ACR/ARHP Annual Meeting
Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies
G. Burmester¹, Ricardo Blanco², Andrea Rubbert-Roth³, Thijs Hendrikx⁴, Kenneth Kwok⁵, John Bradley⁶, Samuel H. Zwillich⁶, Birgitta Benda⁷ and Charles A. Mebus⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²Rheumatology, Hospital Universitario Marques De Valdecilla, Santander, Spain, ³Internal Medicine I, University of Cologne, Cologne, Germany, ⁴Pfizer bv, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc., Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA). The efficacy and safety…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].